Cannabinoids produce biochemical and pharmacological effects by interacting with the central cannabinoid (CB1) and peripheral cannabinoid (CB2) G protein-coupled receptors. AM630 is a selective CB2 receptor antagonist that binds to CB1 and CB2 receptors with Ki values of 5.2 µM and 31.2 nM, respectively.1 AM630 behaves as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors. 1,2,3
1
Ross, R.A., Brockie, H.C., Stevenson, L.A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol126665-672(1999).
3
Bisogno, T., Ortar, G., Petrosino, S., et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochem Biophys Acta179153-60(2009).
Bisogno, T., Ortar, G., Petrosino, S., et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochem Biophys Acta179153-60(2009).
Ross, R.A., Brockie, H.C., Stevenson, L.A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol126665-672(1999).
Size
Price
Quantity
Subtotal
5 mg
$35.00
$0.00
10 mg
$67.00
$0.00
50 mg
$280.00
$0.00
100 mg
$490.00
$0.00
Bulk
Contact
Cart Total
$0.00
This product is available in custom sizes and/or larger quantities.